Review
Nature Reviews Cancer 3, 11-22 (January 2003) | doi:10.1038/nrc969
Targeting RAS signalling pathways in cancer therapy
Julian Downward1 About the author
Abstract
The RAS proteins control signalling pathways that are key regulators of several aspects of normal cell growth and malignant transformation. They are aberrant in most human tumours due to activating mutations in the RAS genes themselves or to alterations in upstream or downstream signalling components. Rational therapies that target the RAS pathways might inhibit tumour growth, survival and spread. Several of these new therapeutic agents are showing promise in the clinic and many more are being developed.
- View At a Glance
Author affiliations
-
Cancer Research UK, London Research Institute, 44 Lincoln's Inn Fields, London WC2A 3PX, UK.
Email: julian.downward@cancer.org.uk
|
MORE ARTICLES LIKE THIS These links to content published by NPG are automatically generated NEWS AND VIEWS RESEARCH |
